The Use of FOLFOX4 Regimen in Stage IV Cervical Cancer: A Pilot Study
| Autor: | Nantaka Pukanhaphan, Bongkot Supawongwattana, Wimrak Onchan, Pitchayaponne Klunklin, Somvilai Chakrabandhu, Ekkasit Tharavichitkul, Ekkapong Tharavichitkul, Imjai Chitapanarux |
|---|---|
| Rok vydání: | 2016 |
| Předmět: |
Cervical cancer
medicine.medical_specialty Anemia business.industry medicine.disease Gastroenterology Surgery Oxaliplatin Metastasis 03 medical and health sciences Folinic acid Regimen 0302 clinical medicine 030220 oncology & carcinogenesis Internal medicine medicine 030212 general & internal medicine Adverse effect business Stage IV cervical cancer medicine.drug |
| Zdroj: | Journal of Cancer Therapy. :297-302 |
| ISSN: | 2151-1942 2151-1934 |
| Popis: | Objective: To evaluate the efficacy and safety of FOLFOX4 (oxaliplatin/5FU/Leucovorin) for the treatment of metastatic cervical cancer. Methods: All patients were designed to receive the FOLFOX4 regimen (Oxaliplatin (Eloxatin®) 85 mg/m2 D1, 5-Fluorouracil 400 mg/m2 IV push D1-2, 5-Fluorouracil 600 mg/m2 IV drip in 22 hours D1-2 and Folinic acid 200 mg/m2 IV push in D1-2). The treatment responsiveness and toxicities were evaluated. Results: Thirty patients from January 2010-December 2012 were enrolled into the study. The mean age was 51 years old. Nine patients (31%) achieved objective response. At the mean follow-up time of 13 months, the one-year progression-free and overall survival rates were 20.7% and 65.5%, respectively. The most common grade 3 adverse event reported in this study was anemia (36.7%), thrombocytopenia (16.7%) and fatigue (16.7%). Conclusions: FOLFOX4 regimen in metastatic cervical cancer is feasible. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|